Liver Diseases  >>  onartuzumab (RG3638)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
onartuzumab (RG3638) / Roche
NCT01897038: A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma

Checkmark P1 MetMab + sorafenib combination trial for hepatocellular carcinoma on hold
Apr 2014 - Apr 2014: P1 MetMab + sorafenib combination trial for hepatocellular carcinoma on hold
Completed
1
9
US, RoW
Onartuzumab, RO5490258, Sorafenib
Hoffmann-La Roche
Carcinoma, Hepatocellular
03/15
03/15

Download Options